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Clinical failures: the tip of the iceberg? 
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In pneumococcal meningitis, it is well accepted that resistance in Streptococcus pneumoniae compromises clinical 
outcome. However, the clinical impact of increasing resistance on community-acquired respiratory tract infections 
(RTIs) is less clear. Bacteriological eradication should be the aim of antimicrobial therapy. The pharmacodynamics 
(potency and pharmacokinetics) of an antimicrobial agent against the infecting pathogen can be used to predict the 
potential for bacterial eradication. Surveillance of clinical isolates from community-acquired RTIs shows that, in 
many countries, there is a trend towards an increasing prevalence of drug-resistant S. pneumoniae. Results from a 
number of published clinical trials suggest that resistance has not compromised the clinical efficacy of 
aminopenicillins when used at the correct dose. However, emerging data indicate that resistance is compromising 
the efficacy of some other routinely used antimicrobials. There are reports of clinical and bacteriological failure 
with macrolides and fluoroquinolones in patients with community-acquired pneumonia. Recent retrospective 
analyses and increasing sporadic reports of clinical failure with these agents may be more representative of the true 
situation. These reports suggest a need to reassess current empirical therapeutic recommendations for the treatment 
of community-acquired RTIs. 
Key words: antimicrobial agent; bacteriological eradication; community-acquired respiratory tract infections; 
pneumococcal resistance; treatment failure. 
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Introduction 
Surveillance studies of clinical isolates from community- 
acquired respiratory tract infections (RTIs) show that the 
prevalence of resistant pathogens is rising, and that MICs 
among these resistant isolates are increasing for a range of 
antimicrobial agents. In recent years, the prevalence of 
drug-resistant Streptococcus pneumoniae has increased 
dramatically. 
The Alexander Project is an ongoing, worldwide, 
surveillance study of bacterial resistance in RTI pathogens. 
Data from the 1997 Alexander Project indicated that the 
estimated worldwide prevalence of penicillin-resistant S. 
pneumoniae was 14.1% (1) and was 22% in 1998 (see Craig, 
‘Introduction’, this issue). Within Europe, there is a great 
deal of variation in the prevalence of penicillin-resistance 
and, in the U.S.A., susceptibility testing of 1456 strains of 
S. pneumoniae in 1998 showed that 14.9% were inter- 
mediate and 31% resistant to penicillin (2). There has also 
been a striking increase in macrolide-resistant S. pneumo- 
niae, with a worldwide estimated prevalence of 27.9% 
(erythromycin MICs > 1 pgml-‘) (3). In Europe, particu- 
larly high prevalence rates are seen in the South and, in the 
U.S.A., the prevalence of macrolide resistance is similar to 
that of penicillin resistance at 34.3%. In some countries, 
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significant cross-resistance between penicillins and macro- 
lides has been found. For example, in the U.S.A., 5.6% of 
penicillin-susceptible strains are macrolide-resistant, com- 
pared with 47% of intermediate and 75% of resistant 
isolates (3). The highest prevalences of macrolide resistance 
are seen currently in South East Asia. For example, a study 
in 1997 in China found that 75% of pneumococci isolated 
from children were macrolide resistant whereas only 14% 
were resistant to penicillin (4). 
The emergence of multiple drug-resistant S. pneumoniae 
(DRSP) has not only complicated the empirical treatment 
of RTIs, but has also led to increased numbers of treatment 
failures (5). In the light of such data, clinicians are 
beginning to show concern about the potential for 
treatment failure with routinely used agents-/?-lactams, 
macrolides and fluoroquinolones-and to question the 
relevance of current therapeutic guidelines. Many older 
antimicrobials (e.g. some macrolides) were recommended 
before the emergence of resistance in RTI pathogens. As 
prescribing for community-acquired RTIs is empirical, i.e. 
with no knowledge of either the infecting pathogen or its 
susceptibility, therapeutic guidelines must take into account 
local susceptibility patterns. 
The effects of increased antibiotic resistance are observed 
first in infections at sites of restricted drug penetration, e.g. 
meningitis and acute otitis media (AOM) (6). This is 
because therapeutic concentrations at these sites are more 
difficult to achieve. In meningitis, for example, increased 
levels of DRSP have compromised clinical outcomes for 
0 2001 HARCOURT PUBLISHERS LTD 
S6 J. GARALJ 
patients, and this has necessitated changes in the antibiotic 
regimens used to treat this disease (5,7). Given the current 
levels of pneumococcal resistance, and the marginal activity 
of some antimicrobial agents against S. pneumoniue, it 
would seem likely that treatment failure in community- 
acquired RTIs will occur more and more commonly. 
Pharmacokinetic (PK) and pharmacodynamic (PD) 
parameters derived from animal and clinical models of 
infection can be used to predict the bacteriological efficacy 
of antimicrobial agents. For p-lactams and macrolides, the 
length of time above MIC is the key parameter; for 
fluoroquinolones and azalides, it is the AUC,,/MIC ratio 
that is important. These parameters provide a mechanism 
for determining the potential for clinical efficacy of a 
particular treatment for a given resistance profile (see Craig, 
‘Re-evaluating current antibiotic therapy’, this issue). 
Although the results of clinical trials appear to suggest 
that resistance has not compromised clinical outcome, such 
trials routinely exclude patients with suspected resistant 
pathogens. Furthermore, some may have been conducted 
prior to the current prevalences of pneumococcal resis- 
tance. Recent retrospective analyses and increasing spora- 
dic reports of clinical failure due to resistance may reflect 
just the ‘tip of the iceberg’. 
Clinical response alone cannot be used as a measure of 
antibiotic efficacy, as community-acquired RTIs are asso- 
ciated with a high rate of spontaneous cure, and differences 
between antimicrobials are therefore masked (8). Cases of 
clinical failure are more informative, as they are often 
related to pathogen persistence. Their review may help to 
shed light on whether current guidelines for the treatment 
of community-acquired RTIs, such as AOM and pneumo- 
nia, need to be re-evaluated. 
Pneumococcal resistance and clinical 
failure in acute otitis media 
Commonly AOM occurs in children, and is generally a mild 
infection with a high spontaneous recovery rate. The most 
common pathogens involved in AOM are S. pneumoniae 
(25-40% of bacterial isolates) and Haemophilus injluenzae 
(20-30% of isolates) (9). In some cases, infections 
associated with S. pneumoniae can lead to serious complica- 
tions, such as mastoiditis, bacteremia, meningitis and 
auditory sequelae (9). Although macrolides are often used 
to treat AOM, current guidelines recommend amoxicillin 
for first-line use (5), and no agent has yet shown superiority 
to amoxicillin/clavulanate in a comparative trial (9). 
Amoxicillin is highly effective against pneumococci and 
displays the most favorable pharmacodynamic profile 
(longest time above MIC) against DRSP of any of the 
commonly available oral agents (5,10,11). 
In vitro susceptibility testing cannot predict clinical 
efficacy, but bacteriological eradication from middle ear 
fluid can be measured reliably, using ‘in vivo’ testing with 
double tympanocentesis. In this technique, a sample of 
middle ear fluid is taken directly before antibiotic therapy 
and a second one during therapy. In randomized, 
comparative trials, this method permits efficacy differentia- 
tion between agents on the basis of bacteriological 
eradication without the need for the large numbers of 
subjects which would be required to detect differences in 
clinical efficacy (8). In a study of bacteriological failure in 
78 children, treated with either cefaclor or cefuroxime 
axetil, Dagan et al. estimated that a sample size of around 
900 patients (450 per treatment arm) would be required to 
detect a statistical difference in clinical efficacy at the 5% 
level (12). 
Optimal clinical success in AOM requires bacteriological 
eradication from middle ear fluid (13). For example, 
in a prospective study of 123 children being treated 
with cefaclor (40mgkgg’day-‘), azithromycin 
(10 mg kg-’ day- ‘) or amoxicillin (50 mg kg-’ day- I), 
Dagan et al. (13) reported clinical success in 64 of 66 
patients (97%) with bacteriological eradication compared 
with just 36 of 57 patients (63%) with bacteriological failure 
(P<O.OOl). The signs and symptoms of infection also 
resolved faster in those patients with bacteriological 
eradication 
Compromised clinical outcomes with certain antimicro- 
bial agents as a result of resistant pathogens have now been 
described in AOM. In addition, agents with poor penetra- 
tion into middle ear fluid (e.g. some cephalosporins and 
macrolides) are unlikely to be able to achieve the 
therapeutic concentrations required for bacteriological 
eradication. The effect of resistance on therapy can be 
investigated by examining differences in the rates of 
bacteriological eradication between agents against patho- 
gens with different in vitro susceptibilities. 
Various studies have used double tympanocentesis to 
evaluate whether bacteriological and clinical outcomes are 
compromised by pneumococcal resistance. The earliest of 
these assessed clinical outcome during oral cephalosporin 
therapy-either cefuroxime axetil, 30 mg kg- ’ day- ‘, or 
cefaclor, 40 mg kg- i day-‘-for penicillin-intermediate S. 
pneumoniae infection (12). Among the 78 isolates of S. 
pneumoniae, 31 (40%) were penicillin intermediate (MIC 
0.125-l .O pg ml- ‘). Overall, the bacteriological failure rate 
was 3 of 47 (6%) patients with susceptible pneumococci and 
11 of 31 (35%) patients with penicillin-intermediate 
pneumococci (P<O.OOl). The bacteriological failure rates 
for each agent were found to be directly proportional to the 
penicillin MIC. Although both drugs were equally effective 
against susceptible pneumococci, results were better for 
cefuroxime axetil than for cefaclor for those pneumococci 
with intermediate resistance, at failure rates of 22% versus 
58%, respectively. A minor increase of MIC to penicillin to 
the 0.125-0.25pgml-’ range did not appear to affect the 
response to cefuroxime axetil but seriously impaired the 
response to cefaclor. The investigators also showed that 
clinical outcome was compromised where resistant patho- 
gens were present. Clinical failure was observed in 9 of 14 
patients (64%) with bacteriological failure versus 10 of 52 
(19%) patients with bacteriological eradication (P = 0.003). 
Similarly, a comparison of the bacteriological efficacies 
of the azalide, azithromycin (10mg kg-’ o.d. daily for 3 
days) and cefaclor (40mg kg-’ day-’ t.d. for 10 days) also 
found that clinical outcome was compromised when 
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resistant pathogens were present (14). For both agents, 
there was a clear correlation between the persistence of S. 
pneumoniae and increased drug MICs. For azithromycin, 
there were no bacteriological failures among patients with 
macrolide-susceptible pneumococci (MIC<O.06 ,ug mll ‘), 
but all patients with macrolide-resistant pneumococci 
(MICz32 pgrnl-‘) experienced bacteriological failure. In 
the cefaclor group, bacteriological failure was observed in 3 
of 14 (21%) patients infected with strains of S. pneuwloniae 
with cefaclor MICs <0..5,~~gmll’, and in 13 of 19 (68%) 
patients with strains of S. pneumoniae with cefaclor 
MICs >0.5pgml-i (P=O.O5). 
A subsequent study involving 238 children with AOM 
provided more evidence of clinical failure with the 
macrolide azithromycin (15). This compared the bacter- 
iological and clinical efficacies of a standard dose of 
amoxicillin/clavulanate (45/6.4 mg kg- ’ day-’ b.d. for 10 
days) and azithromycin (10 mg kg- ’ on day 1, followed by 
5 mg kg-’ day-’ for 4 days). Interestingly, there was a high 
prevalence of penicillin-non-susceptible (59%) and macro- 
lide-resistant (24%) S. pneumoniae isolates in the study 
group. While bacteriological success was clearly related to 
MIC for azithromycin, there was no relationship between 
bacteriological outcome and MIC for amoxicillin/clavula- 
nate at the MICs encountered in this study (Fig. 1). 
Amoxicillin/clavulanate was highly effective in eradicating 
S. pneumoniae isolates including two strains with penicillin 
MICs of > 2 ,ug ml- ‘. Overall, amoxicillin/clavulanate led 
to a higher rate of S. plzeumoniae eradication than 
azithromycin (90% verSUS 68%, NS). 
Though there were significant differences in bacteriolo- 
gical eradication between the two agents in this study, this 
translated into only a modest difference in clinical success 
between amoxicillin/clavulanate compared with azithromy- 
tin (86% veT’sus 80%, NS). This illustrates the effect of the 
high spontaneous resolution rate seen in AOM - termed the 
‘Pollyanna Phenomenon’ by Marchant et al. (8) - which 
masks differences between highly active and less active 
antimicrobials. The clinical difference may seem small, but 
given the number of episodes of AOM, even a small 
P = 0.004 
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Amoxicillid Amoxicillin/ Azithromycin Azithromycin 
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FIG. 1. Effect of resistance to penicillin and macrolides on 
the efficacy of amoxicillin/clavulanate and azithromycin 
(15). 
increase in clinical failure rates due to the spread of 
resistant organisms can translate into a significant increase 
in the number of failures. For example, there are about 20 
million episodes of AOM per year in the U.S.A. A 6% 
difference in failure rates therefore translates into 1.2 
million additional failures per year. It is more difficult to 
estimate the impact of the increased risk of selection and 
spread of resistant isolates. Thus, clinical studies should 
aim to detect differences between antimicrobials, rather 
than comparing clinical success rates. 
Pneumococcal resistance and clinical 
failure in pneumonia 
Community-acquired pneumonia (CAP) remains one of the 
leading causes of morbidity and mortality (6). It is a 
common cause of hospitalization in adults, and places a 
heavy burden on health services. S. pneumoniae is the most 
frequently isolated pathogen in CAP, and is associated with 
more severe disease than other causative pathogens, such as 
H. infhenzae and others (6). For these reasons, S. 
pneumoniae must be viewed as the pivotal pathogen for 
determining empirical treatment of pneumonia in the 
community. 
/!3-LACTAM THERAPY 
As a group, /Llactam antimicrobials have good penetration 
into the lung, and penicillin is still the drug of choice for 
CAP due to its excellent activity against S. pneumoniae. 
According to a report by the Drug-resistant Streptococcus 
pneumoniae Therapeutic Working Group (6) patients with 
S. pneumoniae pneumonia caused either by penicillin- 
susceptible (CO.06 pg ml- ‘) or -intermediate (0. l- 
1 pgmll ‘) isolates respond well to standard doses of b- 
lactam antimicrobial agents. There are conflicting data, 
however, on the outcome of p-lactam treatment for 
pneumonia caused by pneumococcal strains with penicillin 
MICs in the resistant range (>2/*gml-‘). 
One of the problems in evaluating the available data is 
variability in the classifications used for S. pneumoniae 
penicillin resistance. In a study carried out in 1995, Pallares 
et al. (16) found that, during treatment with either 
benzylpenicillin or ampicillin, patients they had defined as 
having penicillin-resistant S. pneumoniae infection 
(MIC 20.12 ,ng ml-‘) had an increased risk of mortality 
compared with patients infected with susceptible 
(<0.06 pg ml-‘) isolates (38% versus 24%, respectively, 
P=O.OOl). Once these data were controlled for independent 
predictors of mortality, however, the risk of mortality was 
found to be similar whether patients were infected with 
‘resistant’ S. pneumoniae or not (25% versus 19%, 
respectively, NS). This may be due to the fact that most 
of the isolates in the study had penicillin MICs that would 
now be considered as being of intermediate resistance 
(51 pgml-‘). Only one isolate had a MIC that would 
currently be classified as resistant (>2,~~grnl-I). Another 
study (17), in patients with pneumococcal bacteremia, 
indicated that infection with penicillin-resistant 
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5’. pneumoniue (MIC >2 pg ml- ‘) was indeed independently 
associated with mortality. However, more than half of the 
patients in the study also had documented HIV infection, 
which makes it difficult to draw any conclusions about the 
impact of resistance per se in the general population. In 
addition, very few patients in this study received penicillin, 
most having been treated with vancomycin and/or ceftriax- 
one. 
High-level penicillin resistance has been associated with 
increased mortality. Feikin et al. (18) showed that 
pneumonia patients infected with high-level penicillin- 
resistant S. pneumoniae (MIC >4pgmll’) were 7.1 times 
more likely to have a poor clinical outcome than patients 
infected with penicillin-susceptible isolates. However, there 
was only a small number of patients with penicillin MICs as 
high as 4pgml-‘, prohibiting statistical analysis; further- 
more, the antibiotic regimens used during treatment were 
not made clear. It is, therefore, difficult to know whether 
patients were given appropriate treatment. Additionally, no 
adjustments were made for disease severity. 
MACROLIDE THERAPY 
In the clinical setting, treatment failure in CAP due to 
macrolide resistance in S. pneumoniae was first reported in 
1992 during erythromycin therapy (19). Needle aspiration 
of the lung, from the two patients involved, revealed 
erythromycin-resistant pneumococci (MIC > 8 ,ug ml-‘). 
The patients responded successfully to /I-lactam therapy. 
To date, a center at the Hospital de Mutua de Terrassa, in 
Barcelona, Spain (20), has documented 18 cases of 
treatment failure on therapy with macrolides (azithro- 
mycin, erythromycin, clarithromycin and josamycin) in 
patients with pneumococcal pneumonia, all of whom were 
subsequently treated effectively with p-lactams (Table 1). 
Nine patients from Barcelona, Spain, and three from 
Providence, U.S.A., developed bacteremia with a macro- 
lide-resistant S. pneumoniae while receiving a macrolide. All 
patients had pneumonia except for one who had no 
identifiable site of infection. Five were children (all from 
Barcelona) and seven were adults. Three had received 
erythromycin, four azithromycin, three clarithromycin and 
two josamycin for a median of 3 days prior to detection of 
bacteremia. All the isolates from Barcelona had the erm 
gene. One isolate from Providence had the mef gene. 
These data are supported by a study by Kelley et al. in 
patients admitted to hospital with pneumococcal bacter- 
emia (21). Of 41 patients admitted, four had previously 
been treated with either azithromycin or clarithromycin for 
3-5 days as outpatients. All four of these clinical failures 
had strains of pneumococci with low-level macrolide 
resistance (erythromycin MICs 8-16 ,ug ml- I). Although 
the mechanism of resistance was not directly tested, all four 
of the erythromycin-resistant strains were susceptible to 
clindamycin (21). These data suggest that low-level macro- 
lide resistance due to the mefE gene may also be associated 
with clinical failure. Studies in an animal model of 
pneumococcal pneumonia also show failure with azithro- 
mycin (22). Animals were infected intrabronchially to 
produce pneumonia, and therapy with oral agents was 
initiated 24 hours later. Azithromycin was shown to be 
ineffective against strains of S. pneumoniae resistant to both 
penicillin and macrolides (Fig. 2). 
There are two key mechanisms of macrolide resistance 
in S. pneumoniae. The first of these results from mutations 
in the ermB gene, which alters the ribosomes of S. 
pneumoniae in such a way that macrolides can no 
longer affect them (23). This produces very high 
levels of resistance, for example azithromycin and 
erythromycin MIC9as > 32 pg ml-’ and clarithromycin 
MICsa > 128 pgml-‘. Clinically, in the presence of ermB 
mutations in S. pneumoniae, it is not possible to increase the 
serum macrolide concentration high enough to overcome 
these resistant organisms. Mutations in the mefE gene- 
encoding a macrolide efflux pump-produce low-level 
macrolide resistance (24). Whether the concentrations at 
the site of infection achieved clinically with macrolides are 
TABLE 1. Outcomes in patients with macrolide-resistant pneumococcal infections experiencing clinical failure while undergoing 
treatment with macrolides. Reproduced with permission (20) 





















































sufficient to eradicate S. pneumoniae with the mefE 
mutation is a point of debate. Although preliminary data 
suggest that low-level macrolide resistance does result in 
clinical failure (21) more clinical data are required to 
resolve this question. 
FLUOROQUINOLONE THERAPY 
The prevalence of fluoroquinolone resistance is currently 
low, though a recent study has found levels to be increasing, 
possibly as a result of selective pressure due to increased 
quinolone use (25). Cases of treatment failure during 
therapy with the older fluoroquinolones are well documen- 
ted. Persistence of pathogens, superinfection, distant 
spread and in vivo selection of resistant strains have all 
been reported-particularly for ciprofloxacin (26-29). 
Despite a relatively broad spectrum of activity, older 
fluoroquinolones (e.g. ofloxacin, ciprofloxacin and norflox- 
acin) have poor activity against Gram-positive pathogens, 
including S. pneumoniae. Although ciprofloxacin has had 
some success in treating RTIs, it is not thought to be 
appropriate for the treatment of CAP (30,31). Perhaps this 
is not surprising, given that ciprofloxacin has marginal 
activity against S. pneumoniae (32). The MIC concentra- 
tions for ciprofloxacin against S. pneumoniae range from 1 
to 4/,~gml-‘, whereas peak serum levels of ciprofloxacin, 
after a dose of 500 mg b.d., are around 2,5,~gml-’ (33). 
One case of treatment failure and in vivo selection of 
resistant strains after ciprofloxacin therapy was described 
by Perez-Trallero et al. (26). This involved an elderly male 
patient hospitalized for CAP due to S. pneumoniae serotype 
3 strain. This is a serotype that seldom shows resistance to 
antibiotics. Initial treatment was with ciprofloxacin, 200 mg 
First admission Second admission 
(+ 10 days) 
FIG. 2. Bacterial kill for various antimicrobials in an 
animal model of pneumonia (penicillin- and macrolide- 
resistant strain). GEM: gemifloxacin; CIP: ciprofloxacin; 
GRP: grepafloxacin; LEV: levofloxacin; TRV: 
trovafloxacin; AMX/CA: amoxicillin/clavulanate; CXM: 
cefuroxime; AZI: azithromycin; 0: rats killed at 96 h; 
error bars represent mean and standard deviation. 
Reproduced with permission (22). 
TABLE 2. Clinical selection of quinolone-resistant pneumo- 
cocci in a patient with pneumococcal pneumonia treated 
with ciprofloxacin (200mg i.v., every 12 h, followed by 
500mg orally, every 12h, for 4 weeks). Reproduced with 
permission (26) 
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intravenously, every 12 hours, followed by 500mg orally, 
every 12 hours. The patient responded well and was 
discharged after 4 weeks. Ten days after the end of 
treatment, he was re-admitted to hospital suffering from 
empyema. Culture revealed an S. pneumoniae strain with 
the same serotype and susceptibility to non-quinolone 
agents as previously, except this time it had reduced 
susceptibility to ciprofloxacin and other quinolones (Table 
2). The patient went on to respond well to amoxicillin. 
Likewise, there is already some evidence of clinical failure 
in CAP with levofloxacin therapy due to resistant organ- 
isms (34). 
The newer fluoroquinolones (moxifloxacin, gatifloxacin 
and gemifloxacin) have increased degrees of potency 
against a wider range of Gram-positive pathogens than 
older members of the class and have improved pharmaco- 
kinetics (22,35). Some of these agents may, therefore, have 
increased potential in the treatment of CAP of pneumo- 
coccal etiology. Of these, gemifloxacin is the most active of 
the new oral fluoroquinolones with potent in vivo activity 
against both penicillin- and macrolide-resistant strains of S. 
pneumoniae (MIC 50.03 pg ml-‘) (22). Gemifloxacin has 
been shown to be as effective as amoxicillin/clavulanate in 
eradicating a penicillin/macrolide-resistant S. pneumoniae 
in an experimental pneumococcal lung infection model (22). 
Implications of treatment failures for 
clinical practice 
This paper indicates that resistance does have an impact on 
clinical outcomes in RTI where therapy is sub-optimal. 
Current levels of resistance clearly compromise the efficacy 
of some oral cephalosporins (e.g. cefaclor) in AOM and of 
macrolides (e.g. azithromycin) in both AOM and CAP. 
Older fluoroquinolones (ciprofloxacin and ofloxacin) have 
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marginal activity against S. pneumoniae and may select for 
resistant isolates (26). Although quinolone resistance is 
currently rare, there is already some evidence of clinical 
failure in CAP with the new fluoroquinolone, levofloxacin, 
due to resistant organisms (35). There now appears to be a 
need to reassess appropriate antimicrobial use for empirical 
treatment in the community. 
Some p-lactam antimicrobials, i.e. the aminopenicillins 
(e.g. amoxicillin/clavulanate), continue to demonstrate high 
levels of clinical efficacy in AOM and pneumonia, despite 
increasing levels of pneumococcal resistance. Most cases of 
CAP caused by non-susceptible isolates of S. pneumoniae 
are likely to respond to high doses of aminopenicillins, 
though treatment failures with standard doses may occur at 
higher levels of resistance ( > 4 ,ug ml- ‘). Pharmacodynamic 
studies show that a time above MIC of about 40% is 
predictive of bacteriological efficacy for /?-lactams. Thus, an 
increased dose of aminopenicillin, which achieves a 
sufficient serum concentration, is likely to ensure continued 
efficacy against isolates currently defined as being fully 
penicillin resistant (36). For example, use of the high-dose 
formulation of amoxicillin/clavulanate (14 : 1 90/6.4 
mg kg-’ day-‘) in an in viva model of pneumonia showed 
that efficacy was maintained against S. pneumoniae with 
MICs to amoxicillin of 4 pgml-’ (37). 
Currently, the level of penicillin resistance in S. 
pneumoniae appears to be fairly stable (MICs of 2- 
4,~gml-‘). However, in 1997, clinical isolates of S. 
pneumoniae with amoxicillin MICs of >4pgml-’ were 
found in 29 patients from different cities across France-1 8 
isolates had amoxicillin MICs of 8 pgrnl-’ (38). Fortu- 
nately, such findings are rare, though continued surveil- 
lance is required to detect such high-level resistant 
pathogens early. 
In summary, for the empirical treatment of community- 
acquired RTI, if infection with penicillin- or macrolide- 
resistant S. pneumoniae is suspected, adequate dosing with 
an aminopenicillin (e.g. amoxicillin/clavulanate) or one of 
the newer more potent fluoroquinolones is likely to achieve 
bacterial eradication and therefore increase the potential 
for maximum clinical cure and minimized selection and 
spread of resistance. 
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